23andMe Holding Co. (NASDAQ:ME) Q3 2022 Earnings Conference Call February 8, 2023 4:30 PM ET

Company Participants

Wade Walke - VP, Investor Relations

Anne Wojcicki - CEO & Co-Founder

Joe Selsavage - Interim CFO & Accounting Officer

Kenneth Hillan - Chief Therapeutics Officer

Conference Call Participants

Daniel Grosslight - Citigroup

Steven Mah - Cowen

Gaurav Goparaju - Berenberg

Operator

Good day, and welcome to 23andMe's Fiscal Year 2023 Third Quarter Financial Results Conference Call. At a reminder, this call is being recorded. At this time, all participants are in a listen-only mode. After the prepared remarks, there will a question-and-answer session.

I would now like to turn the call over to [indiscernible] at Argo Partners to lead off the call. Thank you. Please go ahead.

Unidentified Company Representative

Thank you, Justin. Before we begin, I encourage everyone to go to investors.23me.com to find the press release we issued earlier today reporting our financial results for the quarter. A replay of today's webcast will also be available on our website for a limited time within 24 hours after the event.

Please note that certain statements made during this call regarding matters that are not historical facts, including but not limited to management's outlook or predictions for future periods are forward-looking statements. These statements are based solely on information that is now available to us. We encourage you to review the section entitled Forward-Looking Statements in our press release, which applies to this call. Also please refer to our SEC filings, which can be found on our website and the SEC's website for a discussion of numerous factors that may impact our future performance. We will also discuss certain non-GAAP measures. Important information on our use of these measures and reconciliation to US GAAP may be found in our earnings release.

Joining us on our call today are Anne Wojcicki, our Chief Executive Officer and Co-Founder; and Joe Selsavage, our Interim Chief Financial Officer and Accounting Officer. Kenneth Hillan, our Chief Therapeutics Officer will join us for Q&A.

And with that, I'd like to turn the call over to Anne.

Anne Wojcicki

Thank you. We made significant progress in both our consumer and therapeutic business this part quarter as we continue to focus on leveraging our genetic database, the world's largest recontactable database for genetic research to unlock the potential of the human genome to treat and prevent disease like no other company.